<DOC>
	<DOCNO>NCT01759446</DOCNO>
	<brief_summary>To determine relative abuse potential VYCAVERT ( hydrocodone bitartrate acetaminophen ) compare GENERIC H/A ( hydrocodone bitartrate acetaminophen ) crush administer intranasally non dependent , recreational opioid user .</brief_summary>
	<brief_title>Abuse Potential Intranasal VYCAVERT Tablets ( Hydrocodone Bitartrate/Acetaminophen ) Recreational Opioid Users</brief_title>
	<detailed_description />
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<mesh_term>Acetaminophen , hydrocodone drug combination</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>1 . Healthy male and/or female subject age 18 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test . 2 . Subject recreational opioid user NOT dependent opioids base Diagnostic Statistical Manual Mental Disorders Fourth Edition Text Revision ( DSM IV TR ) criterion . A recreational opioid user define user opioids non medical purpose ( i.e. , psychoactive effect ) least 10 occasion within last year least 12 week Screening Visit ( Visit 1 ) . 3 . Subjects must experience intranasal opioid administration , define intranasal use least 3 occasion within last year Screening . 4 . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . 5 . Subject able speak , read , understand English sufficiently comprehend nature study understand inform consent form ( ICF ) consent process . 6 . An informed consent document sign date subject . 7 . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . 1 . Diagnosis substance and/or alcohol dependence ( exclude caffeine nicotine ) , assess Investigator use DSM IV TR criterion . 2 . Has participate , currently participate , seek treatment substance and/or alcohol relate disorder ( exclude nicotine caffeine ) . 3 . Has positive urine drug screen ( UDS ) include tetrahydrocannabinol ( THC ) Screening ( Visit 1 ) . NOTE : Subjects opioid positive THCpositive UDS Visit 1 may test Visit 2 ( Day 0 ) . If UDS test negative , subject proceed Visit 2 . A positive UDS Visit 2 exclude subject participation , unless UDS THCpositive subject continue study discretion Investigator . 4 . Has positive alcohol breath test Screening . Positive result may repeat and/or subject schedule Investigator 's discretion . 5 . Has condition opioid contraindicate ( e.g. , significant respiratory depression , acute severe bronchial asthma hypercarbia , suspect paralytic ileus ) . 6 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>